An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options and restricted stock units to newly hired employees as inducement grants under Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $25.54 per share and vest over four years, while the RSUs also vest over four years. These grants were made as a material inducement to the employees' acceptance of employment with the company.
Schrödinger, Inc. (Nasdaq: SDGR) ha concesso opzioni su azioni non statutarie e unità di stock ristrette ai dipendenti di nuova assunzione come incentivi ai sensi della Regola di Quotazione 5635(c)(4) del Nasdaq. Le opzioni su azioni hanno un prezzo di esercizio di $25.54 per azione e maturano nell'arco di quattro anni, mentre le RSU maturano anch'esse in quattro anni. Questi incentivi sono stati concessi come inducimento sostanziale all'accettazione del lavoro da parte dei dipendenti con l'azienda.
Schrödinger, Inc. (Nasdaq: SDGR) otorgó opciones sobre acciones no estatutarias y unidades de stock restringidas a empleados recién contratados como concesiones de incentivo bajo la Norma de Listado 5635(c)(4) de Nasdaq. Las opciones tienen un precio de ejercicio de $25.54 por acción y se adquieren a lo largo de cuatro años, mientras que las RSU también se adquieren en el mismo período. Estas concesiones se realizaron como un incentivo material para la aceptación del empleo por parte de los empleados en la compañía.
Schrödinger, Inc. (나스닥: SDGR)는 나스닥 상장규칙 5635(c)(4)에 따른 유인부여를 위해 신규 채용된 직원들에게 비법정 주식 옵션과 제한된 주식 단위를 부여하였습니다. 주식 옵션의 행사 가격은 주당 $25.54이며, 4년에 걸쳐 권리가 발생합니다. RSU 또한 4년에 걸쳐 권리가 발생합니다. 이러한 부여는 직원들이 회사와의 고용 계약을 수락하는데 있어 중요한 유인으로 제공되었습니다.
Schrödinger, Inc. (Nasdaq : SDGR) a accordé des options d'achat d'actions non statutaires et des unités d'actions restreintes aux employés nouvellement embauchés en tant qu'attributions incitatives conformément à la Règle de cotation 5635(c)(4) du Nasdaq. Les options ont un prix d'exercice de 25,54 $ par action et se vestissent sur quatre ans, tandis que les RSU se vestissent également sur une période de quatre ans. Ces attributions ont été faites comme une incitation matérielle à l'acceptation de l'emploi par les employés au sein de l'entreprise.
Schrödinger, Inc. (Nasdaq: SDGR) hat neu eingestellten Mitarbeitern als Anreiz gemäß der Nasdaq Listing Rule 5635(c)(4) nicht-statutarische Aktienoptionen und Restricted Stock Units (RSUs) gewährt. Die Aktienoptionen haben einen Ausübungspreis von $25.54 pro Aktie und erstrecken sich über vier Jahre bis zur vollständigen Verfügbarkeit, während die RSUs ebenfalls über einen Zeitraum von vier Jahren verfügbar werden. Diese Zuteilungen wurden als wesentlicher Anreiz für die Annahme der Beschäftigung bei dem Unternehmen gemacht.
Positive
None.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on April 15, 2024, the company granted (i) non-statutory stock options to purchase 3,600 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 9,613 shares of the company’s common stock to nine newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.
The stock options have an exercise price of $25.54 per share, equal to the closing price of Schrödinger’s common stock on April 15, 2024. The stock options have a ten-year term and vest over four years, with 25 percent of the shares underlying the option vesting when the employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee’s completion of each additional month of service over the 36-month period following the first anniversary of the employment start date.
The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee’s completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date.
The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company’s 2021 Inducement Equity Incentive Plan.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The computational platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.
Founded in 1990, Schrödinger has approximately 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.
What type of grants did Schrödinger, Inc. (SDGR) report under Nasdaq Listing Rule 5635(c)(4)?
Schrödinger, Inc. (SDGR) reported granting non-statutory stock options and restricted stock units to newly hired employees as inducement grants under Nasdaq Listing Rule 5635(c)(4).
How many shares of the company's common stock were included in the stock options grant?
The stock options grant included 3,600 shares of Schrödinger, Inc.'s (SDGR) common stock.
What is the exercise price per share for the stock options granted by Schrödinger, Inc. (SDGR)?
The exercise price per share for the stock options granted by Schrödinger, Inc. (SDGR) is $25.54.
How long is the vesting period for the stock options and restricted stock units granted by Schrödinger, Inc. (SDGR)?
The stock options and restricted stock units granted by Schrödinger, Inc. (SDGR) vest over four years.
Under what conditions were the inducement grants made by Schrödinger, Inc. (SDGR)?
The inducement grants made by Schrödinger, Inc. (SDGR) were made as a material inducement to the newly hired employees' acceptance of employment with the company.
schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. the predictive power of schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company nimbus therapeutics. through significant long-term investments in basic research, schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. hundreds of peer-reviewed scientific publications by schrödinger scientists are frequently among the most heavily cited in their fields. founded in 1990, schrödinger has operations in the us, europe, japan, and india, with business part
